Control of cytokine production by human NK cells
控制人类 NK 细胞产生细胞因子
基本信息
- 批准号:8987712
- 负责人:
- 金额:$ 19.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-11 至 2017-04-30
- 项目状态:已结题
- 来源:
- 关键词:Acute Promyelocytic LeukemiaCell LineCell TherapyCellsCellular biologyCharacteristicsClinicalDataDevelopmentDiseaseHumanInformal Social ControlLymphocyteMalignant NeoplasmsMemoryModelingMusNatural Killer CellsPersonsPhenotypePlayProductionProteinsPublishingRattusReagentReportingRodentRoleTestingTherapeuticTranscriptional RegulationWorkZNF145 geneZinc Fingerscytokineinduced pluripotent stem cellkiller T cellkillingsloss of functionnovelparalogous genepublic health relevanceresponsesuccesstranscription factor
项目摘要
DESCRIPTION (provided by applicant): Our lab showed that the transcription factor promyelocytic leukemia zinc finger (PLZF, zbtb16) is essential for the development of the effector functions of natural killer T cells (NKT cells). This highly conserved protein is also expressed in human and rat NKT cells. Lymphocytes that express PLZF take on wholly different characteristics and effector functions than non-PLZF expressing lymphocytes; the cells are arguably transformed into a distinct lineage by the expression of this transcription factor. In contrast to mice and rats, we have shown that PLZF is expressed by all human NK cells. Furthermore, we have shown that NK cells from the only known person in the world to have a biallelic loss of function of PLZF have both an altered phenotype and function. We propose that a novel transcription factor network controls the self-regulation of NK cell responses in humans. This network will be studied by the use of primary human NK cells and by the use of PLZF deficient NK cells that we will differentiate from induced pluripotent stem cells that we made from the PLZF deficient person. These studies are of high significance because, although NK cell therapies hold great promise for the treatment of diseases such as cancer, clinical success has been limited. Understanding activation checkpoints will provide targets for enhancing therapeutic NK cell activity.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Derek B. Sant'Angelo其他文献
Derek B. Sant'Angelo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Derek B. Sant'Angelo', 18)}}的其他基金
PLZF expression in adipose resident natural killer T cells
PLZF 在脂肪驻留自然杀伤 T 细胞中的表达
- 批准号:
10364677 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
PLZF expression in adipose resident natural killer T cells
PLZF 在脂肪驻留自然杀伤 T 细胞中的表达
- 批准号:
10189318 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
Contribution of Innate-like Tregs for Preventing Tissue Inflammation
先天性 Tregs 对预防组织炎症的贡献
- 批准号:
10412729 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
Expression of BTB-ZF Transcriptional Regulators as Biomarkers of Immune System Development
BTB-ZF 转录调节因子的表达作为免疫系统发育的生物标志物
- 批准号:
9092587 - 财政年份:2016
- 资助金额:
$ 19.69万 - 项目类别:
Leukocyte subset identification by single cell analysis of BTB-ZF gene
通过 BTB-ZF 基因的单细胞分析鉴定白细胞亚群
- 批准号:
8705813 - 财政年份:2013
- 资助金额:
$ 19.69万 - 项目类别:
Leukocyte subset identification by single cell analysis of BTB-ZF gene
通过 BTB-ZF 基因的单细胞分析鉴定白细胞亚群
- 批准号:
8444930 - 财政年份:2013
- 资助金额:
$ 19.69万 - 项目类别:
Immunobiology of NKT cell development and function
NKT 细胞发育和功能的免疫生物学
- 批准号:
8099344 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别:
相似海外基金
Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
- 批准号:
23K06731 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
- 批准号:
23K06616 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
- 批准号:
10597799 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
- 批准号:
EP/Y024591/1 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10672364 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
- 批准号:
10385037 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
- 批准号:
10383462 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
- 批准号:
10483063 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
- 批准号:
2752732 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
Studentship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10546865 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别: